

Prior notification of a concentration
(Case COMP/M.5195 — Pfizer/SP Assets)

(Text with EEA relevance)

(2008/C 194/12)

1. On 22 July 2008, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 ⁽¹⁾ by which the undertaking Pfizer Inc. ('Pfizer', United States of America) acquires within the meaning of Article 3(1)(b) of the Council Regulation certain businesses in the field of animal health ('SP Assets') of Schering-Plough Corporation (United States of America) by way of purchase of assets.

2. The business activities of the undertakings concerned are:

- for Pfizer: research, development, production and sale of human and animal healthcare products,
- for SP Assets: EEA-wide rights to animal health products in the areas of swine *E. coli* vaccines, equine influenza and tetanus vaccines, ruminant neonatal and clostridial vaccines, rabies vaccines, companion animal veterinary specialty products, parasiticides and anti-inflammatories.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5195 — Pfizer/SP Assets, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel

⁽¹⁾ OJL 24, 29.1.2004, p. 1.